We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16628 de novo acute leukemia patients after allogeneic stem cell transplantation (allo-SCT). In comparison to CMV-seronegative recipients allografted from a CMV-seronegative donor, cases with CMV seropositivity of the donor and/or the recipient showed a significantly decreased 2-year leukemia-free survival (44% versus 49%, P < .001) and overall survival (50% versus 56%, P < .001), and increased non-relapse mortality (23% versus 20%, P < .001). Both groups showed a comparable relapse incidence and 2-year probability of graft-versus-host disease.
Introduction
Monitoring of cytomegalovirus (CMV) -e.g. using polymerase chain reaction (PCR) -and its (preemptive) treatment (e.g. with ganciclovir) have been implemented in standard algorithms in patients after allogeneic stem cell transplantation (allo-SCT) in the nineties and resulted in a dramatically reduced frequency of CMV disease from 20-30% to less than 5% in most recent years. [1] [2] [3] However, up to 80% of patients still develop CMV infection (i.e. reactivation) after allo-SCT with recipient CMV seropositivity (R-CMV + ), allografting from a donor other than a human leukocyte antigen (HLA)-identical sibling and the use of in vivo T cell depletion (e.g. with alemtuzumab) being the most important risk factors. [3] [4] [5] [6] Despite this, the prognostic significance of (asymptomatic) CMV infection remains controversial in patients after allo-SCT. A significantly reduced relapse incidence (RI) in acute myeloid leukemia (AML) patients after allo-SCT with versus without early CMV replication has been reported recently. [7] [8] [9] These unexpected clinical observations suggesting a `virusversus-leukemia´ effect were further supported by in vitro studies which suggested that CMV might trigger NK-cell mediated anti-leukemia effects. 10 In contrast, other investigators found a negative prognostic influence of CMV infection after allo-SCT and attributed these observations to side effects of antiviral agents used for preemptive CMV treatment, acute graft-versus-host disease (GvHD) -which might be associated with CMV infection -or a high risk for late CMV disease. 1, 11 At present, the prognostic impact of R-CMV + -as a major risk factor for CMV infection and disease -likewise remains only partially understood. 12 Several studies reported a negative prognostic impact of R-CMV + versus recipient CMV seronegativity (R-CMV -) with an absolute decline in overall survival (OS) of up to 40%. [12] [13] [14] [15] However, these studies were rather heterogeneous with regard to the underlying disease (e.g. acute and chronic leukemia, aplastic anemia) and importantly, were not fully restricted to the era of CMV monitoring and preemptive treatment of CMV infection as routine procedures. Data with respect to the prognostic impact of the donor CMV serostatus are even more scarce and conflicting in patients after allo-SCT, albeit the majority of transplant centers currently prefer a CMVseronegative donor for a CMV-seronegative recipient and a CMV-seropositive donor for a CMV-seropositive recipient. 
Patients and Methods

Study design, data collection and criteria for selection
Adult patients (≥ 18 years) with de novo acute lymphoblastic leukemia (ALL) or AML who were allografted between 1998 and 2009 and documented in the EBMT database were included in this retrospective multicenter study. Only patients with full data available on type of conditioning -reduced intensity conditioning (RIC) versus myeloablative conditioning (MAC), remission status of the underlying malignancy at allo-SCT, source of stem cells -i.e. peripheral blood (PB) versus bone marrow (BM) and both donor and recipient CMV serostatus were analyzed (n=16628). This study was performed in accordance with the principles of the Declaration of Helsinki and approved by the Acute Leukemia Working Party (ALWP) of the EBMT group.
Statistical analyses and definitions
The primary endpoints encompassed the probabilities of leukemia-free survival (LFS), RI, non-relapse mortality (NRM) and OS. Secondary endpoints were acute and chronic GvHD. LFS was considered to be survival with no evidence of relapse or progression. Relapse was defined as the presence of more than 5% BM blasts and/or reappearance of the underlying disease. NRM was defined as death without evidence of relapse or progression. OS was defined as the time from allo-SCT to death, regardless of the cause. Acute and chronic GvHD were graded according to previously published criteria. 17 for categorical variables were done using the Fisher's exact or the Chi square test.
Cumulative incidence functions (CIF) were used to estimate RI and NRM in a competing risks setting, since death and relapse are competing together. 19 In order to study chronic GvHD, we considered death in remission as a competing event.
Specific causes of deaths were also estimated using cumulative incidence curves, considering death from any other cause as competing event. Probabilities of LFS and OS were calculated using the Kaplan-Meier estimates. All probabilities are given in percentage. Univariate analyses were performed using Gray's test for CIF and logrank test for LFS and OS. All factors studied were included in the Cox proportional hazards model for all endpoints under study except acute GvHD for which logistic regression was used. 20 All tests were two-sided with type I error rate fixed at .05. In order to take into account for subgroups comparisons, the Bonferroni correction was applied, with an α less than 0.016 for 3 subgroup analyses. Statistical analyses were performed with SPSS 19 (SPSS Inc, Chicago, IL, USA) and R 2.13.2 (R Development Core Team, Vienna, Austria) software packages.
Results
Patients 16628 patients with de novo acute leukemia who were allografted between 1998 and 2009 and reported to the registry of the ALWP of EBMT were included in this study. Patient and transplant characteristics are summarized in Table 1 (for   different donor types see Supplemental Table S1 ). D-CMV -/R-CMV -was recorded in 4287 cases (26%) and in 12341 cases (74%) D-CMV + and/or R-CMV + was present.
CMV-seropositive recipients (n=10638) were preferentially allografted from a CMV-6 seropositive donor (n=7008, 66%), likely reflecting the current strategy of many transplant centers to match recipient and donor according to their CMV serostatus.
12,16
Survival and relapse of the underlying malignancy (univariate analyses)
LFS and OS estimates were 45% and 51% at 2 years, 39% and 43% at 5 years, and 35% and 38% at 10 years after allo-SCT. In comparison to CMVseronegative recipients allografted from a CMV-seronegative donor, cases with D-CMV + and/or R-CMV + showed a significantly decreased 2-year LFS and OS. These observations were mainly correlated with an increased NRM, whereas RI was slightly increased (P = .08; Table 2 ). Furthermore, D-CMV + versus D-CMV -was associated with a significantly reduced LFS (P = .001) and OS (P < .0001) among CMVseronegative recipients. In turn, CMV-seropositive recipients with a CMV-seropositive donor showed a significantly (P = .04) superior OS than those CMV-seropositive recipients with a CMV-seronegative donor, while the LFS was comparable between both groups (P = .24; Table 2 ) was associated with a significantly (P = .002) decreased 2-year cumulative incidence of death due to infection (7.4% versus 9.2%; Supplemental Figure S1 ), while death due to interstitial pneumonitis was only in tendency (P = .02) decreased (0.9% versus 1.4%). In contrast, CMV-seronegative recipients with a CMV-seronegative donor showed a trend (P = .02) towards an increased 2-year probability of death due to secondary malignancies (0.4% versus 0.1%, Supplemental Table S2 ).
When studying possible interactions between CMV serostatus (D-CMV -/R-CMV -versus D-CMV + and/or R-CMV + ) and all other factors, we found a significant interaction between diagnosis and CMV serostatus with regard to LFS (P = .03) and OS (P = .01), reflecting the higher impact of the CMV serostatus in ALL versus AML.
With this background, we analyzed patients with ALL or AML separately and found that the negative impact of D-CMV + and/or R-CMV + on LFS and OS held true in both cohorts (Supplemental Table S3 ).However, this negative prognostic effect was more pronounced in ALL than in AML, resulting in a markedly decreased 2-year OS (46% and 55% in ALL versus 52% and 56% in AML, Figure 1 Table S3 ).
Engraftment and graft-versus-host disease (univariate analyses)
In total, 15804 of 16386 evaluable patients (96%) had a timely and stable neutrophil engraftment which occurred at a median of 16 days (range: 0-121 days)
after allo-SCT (Supplemental Table S4 ). Primary and secondary graft failure was documented in 496 (3%) and 86 (1%) patients, respectively. The donor/recipient CMV serostatus had no significant impact on the frequency of primary or secondary graft failure or on the median time to neutrophil engraftment when analyzing the whole cohort (Supplemental Table S4 ) was associated with a significantly increased 2-year cumulative incidence of neutrophil engraftment among ALL patients but not within the group of AML recipients (Supplemental Table S3 ).
Acute GvHD (II°-IV°) was documented in 4652 patients (29%). It developed in 30% of CMV-seronegative recipients with a CMV-seronegative donor and in 29% of cases with D-CMV + and/or R-CMV + (P = .06). However, comparing CMVseronegative versus CMV-seropositive recipients, the incidence of II°-IV° acute
GvHD was significantly (P < .001) decreased if the recipient was CMV-seropositive (28% versus 31%, Supplemental Table S4 ). Chronic GvHD was observed in 5202 of 13474 evaluable patients (39%) and its 2-year cumulative incidence did not differ significantly comparing R-CMV + versus R-CMV -(44% versus 45%) or D-CMV -/R-CMV -versus D-CMV + and/or R-CMV + (Table 2) .
Multivariate analyses for outcome
We also analyzed the impact of donor/recipient CMV serostatus on LFS, RI, NRM, OS, neutrophil engraftment and GvHD in a multivariate Cox regression model including different patient and transplant characteristics (Table 3 and Supplemental Table S5 ).
Discussion
This study investigated the prognostic impact of donor/recipient CMV serostatus in 16628 de novo acute leukemia patients after allo-SCT. Using univariate and multivariate analyses, D-CMV + and/or R-CMV + was associated with a significant decrease in LFS and OS, and an increase in NRM. These findings indicate that the CMV serostatus has still an important prognostic impact in acute leukemia patients undergoing allo-SCT despite the wide implementation of monitoring and preemptive treatment of CMV in standard algorithms in recent years. [1] [2] [3] Analyzing different causes of death contributing to NRM, we further found that the 2-year probability of death due to infection was significantly increased in the case of D-CMV + and/or R-CMV + . To get more insights in specific causes of death we also analyzed the outcome in a subgroup of 7731 patients with documented CMV reactivation status (Supplemental Table S6 ). Both LFS and OS were significantly reduced in the case of D-CMV + and/or R-CMV + even in patients who did not experience any CMV reactivation until day +100 after allo-SCT. However, also occurrence of CMV reactivation itself was associated with a significantly reduced LFS and OS if using it as a time-dependent covariate. Taken together, these observations confirm the The negative prognostic impact of D-CMV + and/or R-CMV + was apparently stronger in ALL than in AML patients, resulting in a 9%-decline of 2-year OS in ALL.
Such impact on OS is within the range of other prognostic factors well established for this disease, such as patient's age or leukocyte count at diagnosis. 22 Furthermore, the decrease of LFS and OS in the case of D-CMV + and/or R-CMV + was accompanied by an increased RI and NRM in ALL patients. Conversely, the CMV serostatus likewise had a significant impact on NRM -but not on RI -in AML patients.
Since D-CMV + and/or R-CMV + belong to the most important risk factors for CMV reactivation, our findings rather argue against the so-called `CMV-versus-leukemia effect´, in particular in ALL. 2, 3, [7] [8] [9] We analyzed additionally the development of donor/recipient hematopoietic chimerism to elucidate further potential effects of the CMV serostatus on RI. D-CMV + and/or R-CMV + was associated with a significantly reduced frequency of complete hematopoietic donor/recipient chimerism in both ALL and AML (Supplemental Table S7 ). The exact significance of this finding remains to be elucidated since the RI after allo-SCT is determined by many other variables besides hematopoietic chimerism.
In the literature, the influence of the CMV serostatus of the donor remains even more unclear than that of the recipient. 12 A superior outcome for CMVseropositive unrelated stem cell recipients with a CMV-seropositive versus a CMVseronegative donor has been described in one study but not in another; both of them included patients with different underlying disorders (e.g. acute and chronic leukemia, aplastic anemia). 15, 16 In the present study, D-CMV + versus D-CMV -was associated with a significantly decreased LFS and OS among CMV-seronegative recipients in multivariate analysis. However, the donor CMV serostatus had no prognostic impact among CMV-seropositive recipients in these analyses.
Scarce data is available about the impact of the CMV serostatus on engraftment and occurrence of GvHD. 12, 23, 24 In the current study, the incidence of OS in multivariate analysis. The plateau observed for both LFS and OS with 35% and 38%, respectively, at 10 years after allo-SCT suggests that de novo acute leukemia is cured by this approach in a significant proportion of patients.
In conclusion, this comprehensive analysis on the prognostic impact of donor/recipient CMV serostatus in de novo acute leukemia patients focused on the era of preemptive treatment of CMV infection showed that the CMV serostatus still has an important prognostic impact on allo-SCT outcome despite the implementation of sophisticated techniques for monitoring and (preemptive) treatment of CMV in recent years.
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